<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Repolarization-dependent <z:hpo ids='HP_0011675'>cardiac arrhythmias</z:hpo> only arise in hearts facing multiple 'challenges' affecting its so-called repolarization reserve </plain></SENT>
<SENT sid="1" pm="."><plain><z:hpo ids='HP_0001635'>Congestive heart failure</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CHF</z:e>) is one such challenge frequently observed in humans and is accompanied by altered calcium handling within the contractile heart cell </plain></SENT>
<SENT sid="2" pm="."><plain>This raises the question as to whether or not the well-known calcium channel <z:chebi fb="68" ids="48706">antagonist</z:chebi> <z:chebi fb="1" ids="9948">verapamil</z:chebi> acts as an antiarrhythmic drug in this setting, as seen in <z:hpo ids='HP_0011675'>arrhythmia</z:hpo> models without <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CHF</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>According to the study of Milberg et al. in this issue of BJP, the answer is yes </plain></SENT>
<SENT sid="4" pm="."><plain>The results of this study, using a rabbit <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CHF</z:e> model, raise important questions </plain></SENT>
<SENT sid="5" pm="?"><plain>First, given that the model combines <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CHF</z:e> with a number of other interventions that predispose towards <z:hpo ids='HP_0011675'>arrhythmia</z:hpo>, will similar conclusions be reached in a setting where <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CHF</z:e> is a more prominent proarrhythmic challenge; second, what is the extent to which other effects of calcium channel block would limit the clinical viability of this pharmacological approach in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CHF</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>In vivo studies in large animal <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CHF</z:e> models are now required to further explore this interesting, but complex, approach to the treatment of <z:hpo ids='HP_0011675'>arrhythmia</z:hpo> </plain></SENT>
<SENT sid="7" pm="."><plain>LINKED ARTICLE This article is a commentary on Milberg et al., pp </plain></SENT>
<SENT sid="8" pm="."><plain>557-568 of this issue </plain></SENT>
<SENT sid="9" pm="."><plain>To view this paper visit http://dx.doi.org/10.1111/j.1476-5381.2011.01721.x </plain></SENT>
</text></document>